SCHEMBL6016891

SCHEMBL6016891

CN(c1[c]c(Cl)nc(Cc2ccc(NC(=O)c3ccc4ccccc4c3)cc2)n1)C1CCCCC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.45
NR1H4 Q96RI1 2/20 0.45
KMT2A Q03164 4/20 0.44
NPC1 O15118 4/20 0.44
RAB9A P51151 4/20 0.44
MEN1 O00255 3/20 0.43
CASP3 P42574 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
DEGS1 O15121 1/20 0.41
MAPT P10636 2/20 0.41
POLB P06746 1/20 0.41
MCL1 Q07820 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PTGDR2 Q9Y5Y4 4/20 0.41
LMNA P02545 1/20 0.41
ACKR3 P25106 1/20 0.41
KDM4E B2RXH2 1/20 0.41
GPR27 Q9NS67 1/20 0.41
CCR2 P41597 2/20 0.41
SSTR3 P32745 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5961345 0.88 ACKR3 (0.42) TRPV1NR1H4KMT2ANPC1RAB9A
SCHEMBL6016986 0.88 NR1H4 (0.51) NR1H4KMT2ANPC1RAB9AMEN1
SCHEMBL6016947 0.87 KMT2A (0.41) NR1H4KMT2ANPC1RAB9AMEN1
SCHEMBL6886843 0.85 KMT2A (0.49) NR1H4KMT2ANPC1RAB9AMEN1
SCHEMBL5961335 0.85 NR1H4 (0.48) NR1H4KMT2ANPC1RAB9AMEN1
SCHEMBL6016894 0.84 KMT2A (0.50) NR1H4KMT2ANPC1RAB9AMEN1
SCHEMBL6016983 0.83 NR1H4 (0.47) NR1H4KMT2ANPC1RAB9AMEN1
SCHEMBL6016950 0.83 NR1H4 (0.59) NR1H4KMT2ANPC1RAB9AMEN1
SCHEMBL5961323 0.82 NPC1 (0.47) NR1H4KMT2ANPC1RAB9AMEN1
SCHEMBL5961349 0.82 KMT2A (0.46) NR1H4KMT2ANPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1471057-A1 Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2 Bayer HealthCare AG (DE) 2004-10-27 EP claimed
EP-1633726-A1 PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2 Actimis Pharmaceuticals, Inc., (US) 2006-03-15 EP disclosed
WO-2004096777-A1 PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2 ACTIMIS PHARMACEUTICALS, INC. (US) 2004-11-11 WO disclosed